Tag Archives: PTC Therapeutics

PTC THERAPEUTICS EXPANDS INTERNATIONAL COMMERCIAL TEAM

SOUTH PLAINFIELD, NJ February 25, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Guido Schopen, M.D. to General Manager and Head of Medical Affairs for Europe. Dr. Schopen will be responsible for European commercial operations, reporting to Mark Rothera, Chief Commercial Officer of PTC. Continue Reading    

Continue Reading

PTC Therapeutics Announces that Stuart W. Peltz, Ph.D., CEO is the Recipient of the 2014 Dr. Sol J. Barer Award for Vision, Innovation and Leadership

PTC Therapeutics Announces that Stuart W. Peltz, Ph.D., CEO is the Recipient of the 2014 Dr. Sol J. Barer Award for Vision, Innovation and Leadership SOUTH PLAINFIELD, NJ – January 30, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its founder and Chief Executive Officer, Stuart W. Peltz, Ph.D., has been […]

Continue Reading

PTC THERAPEUTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX

SOUTH PLAINFIELD, NJ – December 23, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), effective prior to the market open today. Continue Reading

Continue Reading

PTC THERAPEUTICS TO JOIN RUSSELL 2000 INDEX

SOUTH PLAINFIELD, NJ – September 30, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it was included on the list of quarterly initial public offering additions to the Russell 2000® Index to be effective at the close of the U.S. market on September 30, 2013. Continue Reading

Continue Reading

PTC THERAPEUTICS APPOINTS MARK ROTHERA AS CHIEF COMMERCIAL OFFICER

SOUTH PLAINFIELD, NJ – April 23, 2013 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Mark A. Rothera as Chief Commercial Officer, reporting to Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. Mr. Rothera will be responsible for global commercial functions supporting PTC’s pipeline, including the investigational new drug ataluren. Continue reading

Continue Reading

Lt. Gov. Kim Guadagno tours South Plainfield life science company

SOUTH PLAINFIELD — As part of the final leg of a monthlong tour of life science companies in New Jersey, Lt. Gov. Kim Guadagno visited a South Plainfield company Wednesday that develops drug therapies for patients living with serious and life-threatening conditions and rare disorders. Read More

Continue Reading

ATALUREN PHASE 2 DATA IN NONSENSE MUTATION CYSTIC FIBROSIS PUBLISHED IN THE EUROPEAN RESPIRATORY JOURNAL

SOUTH PLAINFIELD, NJ – July 1, 2011 – PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal. The published three-month data showed that treatment with ataluren resulted in statistically significant […]

Continue Reading

PTC Therapeutics Appoints Robert Spiegel, M.D. As Chief Medical Officer – Jay Barth, M.D. Promoted to Vice President of Clinical Development

SOUTH PLAINFIELD, NJ – MARCH 30, 2011 PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D., FACP as Chief Medical Officer. Dr. Spiegel served previously as Chief Medical Officer of Schering-Plough. PTC also announced today the promotion of Jay Barth, M.D. to Vice President of Clinical Development. http://ptct.client.shareholder.com/releasedetail.cfm?ReleaseID=560666

Continue Reading

PTC Therapeutics Announces Achievement of Milestone in BMI1 Collaboration with the Wellcome Trust

SOUTH PLAINFIELD, NJ – March 2, 2011 – PTC Therapeutics, Inc. (PTC) today announced that it has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers. The research marks a milestone in PTC’s collaboration with the Wellcome Trust and […]

Continue Reading

PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients

SOUTH PLAINFIELD, NJ AND HACKENSACK, NJ – FEBRUARY 1, 2011 – PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new treatments for patients with Duchenne/Becker muscular dystrophy (DBMD). PPMD has awarded PTC a $250,000 grant, with the potential of additional funding, to advance drug […]

Continue Reading
Follow

Get every new post delivered to your Inbox.

Join 86 other followers